Skip to main content

Table 3 Role of industry in trial conduct: comparison between industry-initiated and academy-initiated clinical trials (n=329; no information for 1 trial)

From: Publication of clinical trials on medicinal products: follow-up on trials authorized in Hungary

 

Industry-initiated clinical trials

(n = 320)

%

Investigator-initiated clinical trials

(n = 9)

%

Financial background

 Founded by the industry

96.88

11.11

 Founded by non-industry

0

55.55

 No information available

3.13

33.33

Trial design

 RCT

79.69

88.88

 Non-RCT

16.88

11.11

 No information available

2.81

0

Blinding

 Double-blind

62.19

44.44

 Single-blind

1.25

0

 Open-label

21.88

44.44

 Not clear

14.69

11.11

Collaboration

 National

1.88

44.44

 International (only EEA)

88.75

33.33

 International (within and outside the EEA)

9.375

22.22

Trial scope

 Safety and efficacy

93.75

55.55

 Safety

5

0

 Efficacy

1.25

33.33

 None

0

11.11

Trial phase

 Phase I

1.5625

0

 Phase II

38.75

0

 Phase III

52.8125

55.55

 Phase IV

4.0625

22.22

 Not mentioned/More phases

2.8125

22.22

Data monitoring committee

 Yes

55.31

33.33

 No

44.69

66.66

Availability of study results

 Results posted in EU CTR

73.125

11.11

 Results published as full scientific publication

62.8125

55.55

 Time to publication (months; mean [SD])

21.70 [16,82]

18.33 [3,77]

Impact on the scientific reputation of the authorizing country

 Publication with at least one Hungarian author

12.1875

33.33

 Publication mentioning Hungarian participant(s)

27.5

44.44